Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
In that same month, in clashes between the Comando Vermelho and the militias, 10 people were killed. Residents were threatened by the fighting groups and the president of an association for local residents was kidnapped and subsequently disappeared. On 5 August, one of the leaders of the militia, Carlos Alexandre Silva Cavalcante, known as "Gaguinho", was killed. On 20 August 2008, the militias carried out a massacre which resulted in the death of 7 people in the Carobinha favela in a false flag operation aiming to frame the Comando Vermelho for the massacre. There was also an attempt to enforce the political candidacy of Carminha Jerominho, daughter of Jerônimo Guimarães Filho, alias "Jerominho", the leader of a militia faction. On 5 October, "Mineiro da Cidade Alta" was killed by the militias for the murder of several militia members. From 2007 to 2008, three politicians were arrested for providing support to the militias: Josinaldo Francisco da Cruz (known as "Nadinho de Rio das Pedras"), Natalino José Guimarães and his brother Jerônimo Guimarães. On 9 June 2009, Josinaldo Francisco da Cruz was killed. Despite initially being opposed to drug trafficking, many militia groups (such as the "Liga da Justiça" faction) have allied themselves with cartels like the TCP, while also recruiting many former drug traffickers, informants and ex-convicts into their ranks, sometimes through coercion.
Diabetic retinopathy is an ocular pathology in diabetics which results in weakening of the retinal blood vessels. The initial nonproliferative stage is characterised by leaky vessels. As the vessel damage is repaired over time, they eventually become occluded, leading to proliferative diabetic retinopathy. The occluded capillaries create areas of ischemic retina and trigger the release of angiogenic growth factors. These growth factors stimulate the proliferation of new blood vessels from pre-existing retinal venules. It is the leading cause of blindness of working age adults.
=== Shipping and logistics === The company provides shipping and multimodal logistics services. Its shipping services include containerized, bulk, and tanker cargo transportation. The group's logistics services include third-party logistics, freight forwarding, cold chain logistics, and warehousing. In 2022, Transworld Group entered the liquid bulk segment with the purchase of two vessels of 74,000 DWT, flying the Panama flag. Between 2021-24, Transworld Group provided logistics services in the construction of the BAPS Hindu Mandir in Abu Dhabi. In 2023, Transworld Group signed an agreement with DP World's Jebel Ali Free Zone (Jafza) for the construction of a 50,000+ square meters, dry and temperature-controlled distribution center in Jafza, which is expected to be completed by 2025. In 2024, Transworld Group signed a ₹2,000 crore MoU to establish ship leasing and aircraft leasing activities at GIFT IFSC, Gujarat.
Sources: en.wikipedia.org
=== 1971 === January 25: Idi Amin launches a successful coup d'état against Milton Obote in Uganda and declares himself President of Uganda. Under Amin, Uganda would switch allegiances to the Eastern Bloc and develop strong ties to the Soviet Union and East Germany. February 8: South Vietnamese forces enter Laos to briefly cut the Ho Chi Minh Trail. February 11: Seabed Arms Control Treaty is signed banning the placement of nuclear weapons outside of a country's 12-mile (22.2 km) coastal zone. March 10: Dominion of Ceylon declared under emergency conditions after communist People's Liberation Front attacks the American embassy. March 25 : Bangladeshi genocide From The West Pakistani Troops until 16 December March 26: Bangladeshi Declaration of Independence and Bangladesh Liberation War begin April 19: Salyut 1 is launched becoming the first space station. May 15: Anwar Sadat's Corrective Revolution purges Nasserist members of the government and security forces, and eventually expels the Soviet military from Egypt. May 28: Mars 3 is launched. May 30: Mariner 9 is launched. July 19–22: a communist-backed coup attempted unsuccessfully against Jaafar Nimeiry in Sudan. September: 105 Soviet officials expelled from Great Britain by Prime Minister Edward Heath in Operation FOOT. September 3: Four-Power Agreement on Berlin is signed by the United Kingdom, the Soviet Union, France, and the United States. October 11: Salyut 1 burns up in the atmosphere.
== Production and development == Mulligan Stew was developed in early 1971 by the USDA Extension Service, and filmed by the USDA Motion Picture Service (which for many years prior produced educational cinematic films and TV programs for public viewing). Mulligan Stew was developed based on plan and design proposals by Developmental Committees, Iowa State University Extension Service 4-H Nutrition Television Programs. The Expanded Food and Nutrition Education Program (EFNEP) provided a grant to produce the series. (4-H is the official youth outreach and development program of the land-grant universities' Cooperative Extension Services and USDA.) The target audience of the program was older elementary school students, fourth through sixth grade. Eleanor Wilson, the national 4-H TV coordinator at the time, was tapped to be the series' technical advisor. Wilson subcontracted with Iowa State University to develop an outline of educational concepts for the series. USDA Extension then hired Ira Klugerman to direct the series. Klugerman, who came from a background of children's television at WQED in Pittsburgh, Pennsylvania, came up with the title and general treatment for the series. V. "Buddy" Renfro was the credited producer. Production began on location in southeast Washington, DC in 1971 (the opening sequence was filmed at RFK Stadium). Other filming locations included major production partner Michigan State University's home base of Lansing, Michigan, and on location for one episode at Johnson Space Center in Houston.
Additionally, H-DNA has been shown to cause mutations related to critical cellular processes like DNA replication and transcription. The importance of these processes for survival has led to the development of complex DNA repair mechanisms that allow cells to recognize and fix DNA damage. Non-canonical DNA structures can be perceived as damage by the cell, and recent work has shown an increased prevalence of mutations near non-B-DNA-forming sequences. Some of these mutations are due to the interactions between H-DNA and the enzymes involved in DNA replication and transcription, where H-DNA interferes with these processes and triggers various DNA repair mechanisms. This can cause genetic instability and implicates H-DNA in cancer formation.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.